FDA Determines Regulatory Review Period for PROGENSA PCA3 ASSAY Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the PROGENSA PCA3 ASSAY medical device, as required by law, following a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.